WO2020039443A1 - Compositions and methods for controlling mammalian pathogens - Google Patents
Compositions and methods for controlling mammalian pathogens Download PDFInfo
- Publication number
- WO2020039443A1 WO2020039443A1 PCT/IL2019/050942 IL2019050942W WO2020039443A1 WO 2020039443 A1 WO2020039443 A1 WO 2020039443A1 IL 2019050942 W IL2019050942 W IL 2019050942W WO 2020039443 A1 WO2020039443 A1 WO 2020039443A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- spp
- incl
- composition
- pathogens
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 244000052769 pathogen Species 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims description 38
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000004383 Steviol glycoside Substances 0.000 claims abstract description 12
- 229930182488 steviol glycoside Natural products 0.000 claims abstract description 12
- 235000019411 steviol glycoside Nutrition 0.000 claims abstract description 12
- 150000008144 steviol glycosides Chemical class 0.000 claims abstract description 12
- 235000019202 steviosides Nutrition 0.000 claims abstract description 12
- 239000004471 Glycine Substances 0.000 claims abstract description 11
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims abstract description 11
- 239000004223 monosodium glutamate Substances 0.000 claims abstract description 11
- 235000013923 monosodium glutamate Nutrition 0.000 claims abstract description 11
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960002303 citric acid monohydrate Drugs 0.000 claims abstract description 10
- 241000282887 Suidae Species 0.000 claims description 32
- 241000588724 Escherichia coli Species 0.000 claims description 27
- 230000001717 pathogenic effect Effects 0.000 claims description 23
- 241000700605 Viruses Species 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 15
- 241000186216 Corynebacterium Species 0.000 claims description 15
- 241000590002 Helicobacter pylori Species 0.000 claims description 14
- 229940037467 helicobacter pylori Drugs 0.000 claims description 14
- 241000692844 Prevotellaceae Species 0.000 claims description 12
- 241000589971 Spirochaetaceae Species 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 241000589893 Brachyspira hyodysenteriae Species 0.000 claims description 11
- 241000607142 Salmonella Species 0.000 claims description 11
- 241000589291 Acinetobacter Species 0.000 claims description 10
- 241000272517 Anseriformes Species 0.000 claims description 10
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 10
- 241000701041 Human betaherpesvirus 7 Species 0.000 claims description 10
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 10
- 241000701027 Human herpesvirus 6 Species 0.000 claims description 10
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 10
- 241000588653 Neisseria Species 0.000 claims description 10
- 241000589516 Pseudomonas Species 0.000 claims description 10
- 241000509427 Sarcoptes scabiei Species 0.000 claims description 10
- 241000194017 Streptococcus Species 0.000 claims description 10
- 241000710886 West Nile virus Species 0.000 claims description 10
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 claims description 10
- 244000052616 bacterial pathogen Species 0.000 claims description 9
- 241001502567 Chikungunya virus Species 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 8
- 241000282412 Homo Species 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 241000702670 Rotavirus Species 0.000 claims description 7
- 241000193755 Bacillus cereus Species 0.000 claims description 6
- 241000589876 Campylobacter Species 0.000 claims description 6
- 241000193403 Clostridium Species 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 6
- 241000589989 Helicobacter Species 0.000 claims description 6
- 241000605861 Prevotella Species 0.000 claims description 6
- 102000029797 Prion Human genes 0.000 claims description 6
- 108091000054 Prion Proteins 0.000 claims description 6
- 241000607768 Shigella Species 0.000 claims description 6
- 241000607626 Vibrio cholerae Species 0.000 claims description 6
- 244000045947 parasite Species 0.000 claims description 6
- 241000590020 Achromobacter Species 0.000 claims description 5
- 241001673062 Achromobacter xylosoxidans Species 0.000 claims description 5
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 5
- 241000186361 Actinobacteria <class> Species 0.000 claims description 5
- 241000186046 Actinomyces Species 0.000 claims description 5
- 241000607534 Aeromonas Species 0.000 claims description 5
- 241000588986 Alcaligenes Species 0.000 claims description 5
- 241000588813 Alcaligenes faecalis Species 0.000 claims description 5
- 241000244185 Ascaris lumbricoides Species 0.000 claims description 5
- 241000228212 Aspergillus Species 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 5
- 241000193738 Bacillus anthracis Species 0.000 claims description 5
- 244000063299 Bacillus subtilis Species 0.000 claims description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 5
- 241000606660 Bartonella Species 0.000 claims description 5
- 241000606108 Bartonella quintana Species 0.000 claims description 5
- 102100025142 Beta-microseminoprotein Human genes 0.000 claims description 5
- 241000726107 Blastocystis hominis Species 0.000 claims description 5
- 241000588807 Bordetella Species 0.000 claims description 5
- 241000588832 Bordetella pertussis Species 0.000 claims description 5
- 241000589968 Borrelia Species 0.000 claims description 5
- 241000124827 Borrelia duttonii Species 0.000 claims description 5
- 241000180135 Borrelia recurrentis Species 0.000 claims description 5
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 5
- 241000131407 Brevundimonas Species 0.000 claims description 5
- 241000589539 Brevundimonas diminuta Species 0.000 claims description 5
- 241000589562 Brucella Species 0.000 claims description 5
- 241001453380 Burkholderia Species 0.000 claims description 5
- 241000589513 Burkholderia cepacia Species 0.000 claims description 5
- 241000722910 Burkholderia mallei Species 0.000 claims description 5
- 241000282832 Camelidae Species 0.000 claims description 5
- 241000589875 Campylobacter jejuni Species 0.000 claims description 5
- 241000222173 Candida parapsilosis Species 0.000 claims description 5
- 241000283707 Capra Species 0.000 claims description 5
- 241000606161 Chlamydia Species 0.000 claims description 5
- 241001647372 Chlamydia pneumoniae Species 0.000 claims description 5
- 241001647378 Chlamydia psittaci Species 0.000 claims description 5
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 5
- 241000588923 Citrobacter Species 0.000 claims description 5
- 241000193163 Clostridioides difficile Species 0.000 claims description 5
- 241000193155 Clostridium botulinum Species 0.000 claims description 5
- 241000193468 Clostridium perfringens Species 0.000 claims description 5
- 241000193449 Clostridium tetani Species 0.000 claims description 5
- 241000711573 Coronaviridae Species 0.000 claims description 5
- 241000186225 Corynebacterium pseudotuberculosis Species 0.000 claims description 5
- 241000918600 Corynebacterium ulcerans Species 0.000 claims description 5
- 241000606678 Coxiella burnetii Species 0.000 claims description 5
- 241000709687 Coxsackievirus Species 0.000 claims description 5
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 claims description 5
- 201000007336 Cryptococcosis Diseases 0.000 claims description 5
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 5
- 241000673115 Cryptosporidium hominis Species 0.000 claims description 5
- 241000223936 Cryptosporidium parvum Species 0.000 claims description 5
- 241000179197 Cyclospora Species 0.000 claims description 5
- 241000725619 Dengue virus Species 0.000 claims description 5
- 241000157306 Dientamoeba fragilis Species 0.000 claims description 5
- 241001115402 Ebolavirus Species 0.000 claims description 5
- 241000244160 Echinococcus Species 0.000 claims description 5
- 241001466953 Echovirus Species 0.000 claims description 5
- 241000204733 Entamoeba dispar Species 0.000 claims description 5
- 241000224432 Entamoeba histolytica Species 0.000 claims description 5
- 241000588697 Enterobacter cloacae Species 0.000 claims description 5
- 241000498255 Enterobius vermicularis Species 0.000 claims description 5
- 241000194033 Enterococcus Species 0.000 claims description 5
- 241000194032 Enterococcus faecalis Species 0.000 claims description 5
- 241000194031 Enterococcus faecium Species 0.000 claims description 5
- 241000194029 Enterococcus hirae Species 0.000 claims description 5
- 241000709661 Enterovirus Species 0.000 claims description 5
- 241001529459 Enterovirus A71 Species 0.000 claims description 5
- 241000991587 Enterovirus C Species 0.000 claims description 5
- 241001480035 Epidermophyton Species 0.000 claims description 5
- 241000283086 Equidae Species 0.000 claims description 5
- 241001331845 Equus asinus x caballus Species 0.000 claims description 5
- 241000588722 Escherichia Species 0.000 claims description 5
- 241000589602 Francisella tularensis Species 0.000 claims description 5
- 241000287828 Gallus gallus Species 0.000 claims description 5
- 241000224467 Giardia intestinalis Species 0.000 claims description 5
- 241000606790 Haemophilus Species 0.000 claims description 5
- 241000606768 Haemophilus influenzae Species 0.000 claims description 5
- 241000711549 Hepacivirus C Species 0.000 claims description 5
- 241000700721 Hepatitis B virus Species 0.000 claims description 5
- 241000724675 Hepatitis E virus Species 0.000 claims description 5
- 208000037262 Hepatitis delta Diseases 0.000 claims description 5
- 241000724709 Hepatitis delta virus Species 0.000 claims description 5
- 241000228404 Histoplasma capsulatum Species 0.000 claims description 5
- 101100185029 Homo sapiens MSMB gene Proteins 0.000 claims description 5
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 5
- 241000342334 Human metapneumovirus Species 0.000 claims description 5
- 241000701806 Human papillomavirus Species 0.000 claims description 5
- 241000588915 Klebsiella aerogenes Species 0.000 claims description 5
- 241001534216 Klebsiella granulomatis Species 0.000 claims description 5
- 241000588749 Klebsiella oxytoca Species 0.000 claims description 5
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 5
- 241000712902 Lassa mammarenavirus Species 0.000 claims description 5
- 241001647841 Leclercia adecarboxylata Species 0.000 claims description 5
- 241000589248 Legionella Species 0.000 claims description 5
- 241000589242 Legionella pneumophila Species 0.000 claims description 5
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 5
- 241000222722 Leishmania <genus> Species 0.000 claims description 5
- 241000589902 Leptospira Species 0.000 claims description 5
- 241000589929 Leptospira interrogans Species 0.000 claims description 5
- 241001468196 Leuconostoc pseudomesenteroides Species 0.000 claims description 5
- 241000186781 Listeria Species 0.000 claims description 5
- 241000186779 Listeria monocytogenes Species 0.000 claims description 5
- 208000016604 Lyme disease Diseases 0.000 claims description 5
- 241001115401 Marburgvirus Species 0.000 claims description 5
- 241000712079 Measles morbillivirus Species 0.000 claims description 5
- 201000009906 Meningitis Diseases 0.000 claims description 5
- 241000191938 Micrococcus luteus Species 0.000 claims description 5
- 241001480037 Microsporum Species 0.000 claims description 5
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 5
- 241000700559 Molluscipoxvirus Species 0.000 claims description 5
- 241000588771 Morganella <proteobacterium> Species 0.000 claims description 5
- 241000711386 Mumps virus Species 0.000 claims description 5
- 241000186359 Mycobacterium Species 0.000 claims description 5
- 241000254210 Mycobacterium chimaera Species 0.000 claims description 5
- 241000186362 Mycobacterium leprae Species 0.000 claims description 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 5
- 241000204031 Mycoplasma Species 0.000 claims description 5
- 241000204051 Mycoplasma genitalium Species 0.000 claims description 5
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims description 5
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 5
- 241001263478 Norovirus Species 0.000 claims description 5
- 241000272458 Numididae Species 0.000 claims description 5
- 241000242726 Opisthorchis viverrini Species 0.000 claims description 5
- 241000606693 Orientia tsutsugamushi Species 0.000 claims description 5
- 241000150452 Orthohantavirus Species 0.000 claims description 5
- 241000588912 Pantoea agglomerans Species 0.000 claims description 5
- 241001326098 Paracoccus yeei Species 0.000 claims description 5
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 5
- 241001494479 Pecora Species 0.000 claims description 5
- 241000517307 Pediculus humanus Species 0.000 claims description 5
- 241000517306 Pediculus humanus corporis Species 0.000 claims description 5
- 241000286209 Phasianidae Species 0.000 claims description 5
- 241000235645 Pichia kudriavzevii Species 0.000 claims description 5
- 241000224016 Plasmodium Species 0.000 claims description 5
- 241000142787 Pneumocystis jirovecii Species 0.000 claims description 5
- 241001505332 Polyomavirus sp. Species 0.000 claims description 5
- 241000186429 Propionibacterium Species 0.000 claims description 5
- 241000588770 Proteus mirabilis Species 0.000 claims description 5
- 241000588767 Proteus vulgaris Species 0.000 claims description 5
- 241000125945 Protoparvovirus Species 0.000 claims description 5
- 241000588777 Providencia rettgeri Species 0.000 claims description 5
- 241000588778 Providencia stuartii Species 0.000 claims description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- 241000711798 Rabies lyssavirus Species 0.000 claims description 5
- 241000232299 Ralstonia Species 0.000 claims description 5
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 5
- 241000606701 Rickettsia Species 0.000 claims description 5
- 241000606697 Rickettsia prowazekii Species 0.000 claims description 5
- 241000606726 Rickettsia typhi Species 0.000 claims description 5
- 241001403850 Roseomonas gilardii Species 0.000 claims description 5
- 241000710799 Rubella virus Species 0.000 claims description 5
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims description 5
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 claims description 5
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 5
- 241000369757 Sapovirus Species 0.000 claims description 5
- 241000242680 Schistosoma mansoni Species 0.000 claims description 5
- 241000607715 Serratia marcescens Species 0.000 claims description 5
- 241000607760 Shigella sonnei Species 0.000 claims description 5
- 241000700584 Simplexvirus Species 0.000 claims description 5
- 241000736131 Sphingomonas Species 0.000 claims description 5
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 5
- 241000191940 Staphylococcus Species 0.000 claims description 5
- 241000191967 Staphylococcus aureus Species 0.000 claims description 5
- 241001147736 Staphylococcus capitis Species 0.000 claims description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 5
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims description 5
- 241000192087 Staphylococcus hominis Species 0.000 claims description 5
- 241001134656 Staphylococcus lugdunensis Species 0.000 claims description 5
- 241000193817 Staphylococcus pasteuri Species 0.000 claims description 5
- 241001147691 Staphylococcus saprophyticus Species 0.000 claims description 5
- 241000122973 Stenotrophomonas maltophilia Species 0.000 claims description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 5
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 5
- 241000244177 Strongyloides stercoralis Species 0.000 claims description 5
- 241000244157 Taenia solium Species 0.000 claims description 5
- 241000223997 Toxoplasma gondii Species 0.000 claims description 5
- 241000589886 Treponema Species 0.000 claims description 5
- 241000589884 Treponema pallidum Species 0.000 claims description 5
- 241000243777 Trichinella spiralis Species 0.000 claims description 5
- 241000224527 Trichomonas vaginalis Species 0.000 claims description 5
- 241000223238 Trichophyton Species 0.000 claims description 5
- 241000223230 Trichosporon Species 0.000 claims description 5
- 241001489145 Trichuris trichiura Species 0.000 claims description 5
- 241001442399 Trypanosoma brucei gambiense Species 0.000 claims description 5
- 241001442397 Trypanosoma brucei rhodesiense Species 0.000 claims description 5
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 5
- 241000202898 Ureaplasma Species 0.000 claims description 5
- 241000700618 Vaccinia virus Species 0.000 claims description 5
- 241000700647 Variola virus Species 0.000 claims description 5
- 241000710772 Yellow fever virus Species 0.000 claims description 5
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 5
- 241000607447 Yersinia enterocolitica Species 0.000 claims description 5
- 241000607479 Yersinia pestis Species 0.000 claims description 5
- 241000607477 Yersinia pseudotuberculosis Species 0.000 claims description 5
- 241000907316 Zika virus Species 0.000 claims description 5
- 229940005347 alcaligenes faecalis Drugs 0.000 claims description 5
- 244000309743 astrovirus Species 0.000 claims description 5
- 229940065181 bacillus anthracis Drugs 0.000 claims description 5
- 229940092523 bartonella quintana Drugs 0.000 claims description 5
- 229940011597 blastocystis hominis Drugs 0.000 claims description 5
- 229940074375 burkholderia mallei Drugs 0.000 claims description 5
- 229940055022 candida parapsilosis Drugs 0.000 claims description 5
- 235000013330 chicken meat Nutrition 0.000 claims description 5
- 229940038705 chlamydia trachomatis Drugs 0.000 claims description 5
- 206010013023 diphtheria Diseases 0.000 claims description 5
- 229940007078 entamoeba histolytica Drugs 0.000 claims description 5
- 229940092559 enterobacter aerogenes Drugs 0.000 claims description 5
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 5
- 229940118764 francisella tularensis Drugs 0.000 claims description 5
- 229940085435 giardia lamblia Drugs 0.000 claims description 5
- 244000000013 helminth Species 0.000 claims description 5
- 229940115932 legionella pneumophila Drugs 0.000 claims description 5
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 5
- 229940007042 proteus vulgaris Drugs 0.000 claims description 5
- 229940046939 rickettsia prowazekii Drugs 0.000 claims description 5
- 229940115939 shigella sonnei Drugs 0.000 claims description 5
- 229940037649 staphylococcus haemolyticus Drugs 0.000 claims description 5
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 5
- 229940096911 trichinella spiralis Drugs 0.000 claims description 5
- 230000000766 tuberculocidal effect Effects 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 241000712461 unidentified influenza virus Species 0.000 claims description 5
- 229940118696 vibrio cholerae Drugs 0.000 claims description 5
- 230000003253 viricidal effect Effects 0.000 claims description 5
- 229940051021 yellow-fever virus Drugs 0.000 claims description 5
- 229940098232 yersinia enterocolitica Drugs 0.000 claims description 5
- 241000282472 Canis lupus familiaris Species 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 241000792859 Enema Species 0.000 claims description 4
- 241000282326 Felis catus Species 0.000 claims description 4
- 241000607598 Vibrio Species 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000007920 enema Substances 0.000 claims description 4
- 229940095399 enema Drugs 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- -1 lyophilized Substances 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 claims description 4
- 239000002324 mouth wash Substances 0.000 claims description 4
- 229940051866 mouthwash Drugs 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 229940034610 toothpaste Drugs 0.000 claims description 4
- 239000000606 toothpaste Substances 0.000 claims description 4
- 241001243761 Human hepatitis A virus Species 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 20
- 230000000968 intestinal effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 244000005709 gut microbiome Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 241000709721 Hepatovirus A Species 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000736262 Microbiota Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000001064 degrader Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 230000001454 enterotrophic effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036397 gastrointestinal physiology Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000007540 host microbe interaction Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 1
- 229940032084 steviol Drugs 0.000 description 1
- 238000005496 tempering Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present disclosure relates to compositions and methods for controlling pathogens in mammalian subjects. More particularly, the current invention pertains to a composition and method for reduction of pathogenic bacteria by oral administration of a non- antibiotic isotonic drink.
- Pigs coexist with a diverse and dense commensal microbiota in their gastrointestinal tract. Most of these microbes are beneficial, providing necessary nutrients or protection against harmful pathogens for the host.
- the microbial colonization of the porcine intestine begins at birth and follows a rapid succession during the neonatal and weaning period.
- the intestinal immune system of the newborn piglet is poorly developed at birth and undergoes a rapid period of expansion and specialization that is not achieved before early (commercial-) weaning.
- the animal agriculture sector is a major user of antibiotic drugs for disease treatment, disease control, disease prevention, and“production purposes” (such as growth promotion).
- FIG.l depicting a graphical presentation of a preferred embodiment of the current invention.
- FIG.2 depicting yet another graphical presentation of a preferred embodiment of the current invention.
- composition useful for an antibiotic- free composition for control of pathogens in a mammalian subject characterized by at least three members of a group consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate, glycine, mixtures and derivatives thereof.
- compositions as defined in any of the above wherein said composition is an oral isotonic composition characterized by no residual chlorine taste.
- composition as defined in any of the above, wherein said control is reduction in counts of said pathogens in said mammalian subject compared to control mammalian subject.
- composition as defined in any of the above, wherein said control is elimination of said pathogens in said mammalian subject compared to control mammalian subject.
- compositions as defined in any of the above wherein said animal is selected from a group consisting at least one of human, cattle, pigs, sheep, goats, horses, mules, asses, buffalo, camels, chickens, turkeys, ducks, geese, guinea fowl, squabs, dogs, or cats of any age.
- Astrovirus Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Bacteriodes fragilis, Bartonella quintana, Blastocystis hominis, Bordetella pertussis, Borrelia burgdorferi, Borrelia duttoni, Borrelia recurrentis, Brevundimonas diminuta, Brevundimonas vesicularisBrucella spp., Burkholderia cepacia (incl.
- Corynebacterium diphtheria Corynebacterium pseudotuberculosis, Corynebacterium spp., Corynebacterium ulcerans, Coxiella burnetii, Coxsackievirus, Crimean-Congo haemorrhagic fever virus, Cryptococcus neof ormans, Cryptosporidium hominis, Cryptosporidium parvum e, Cyclospora cayetanensisCytomegalovirus
- EHEC EHEC
- EPEC ETEC
- EIEC EAEC
- ESBL/MRGN DAEC
- Filarial worms Foot-and-mouth disease virus (FMDV)
- Francisella tularensis Giardia lamblia, Haemophilus influenza, Hantavirus, Helicobacter pylori, Helminths (Worms), Hepatitis A virus
- HAV Hepatitis B virus - HBV
- Hepatitis C virus - HCV Hepatitis D virus
- Hepatitis E virus Herpes simplex virus - HSV, Histoplasma capsulatum
- Human enterovirus 71 Human herpesvirus 6 (HHV-6), Human herpesvirus 7 (HHV-7), Human herpesvirus 8 (HHV-8), Human immunodeficiency virus - HIV, Human metapneumovirus, Human papillomavirus, Hymenolepsis nana, Influenza virus, Klebsiella granulomatis, Klebsiella oxytoca (incl. ESBL/MRGN), Klebsiella pneumoniae MDR (incl.
- ESBL/MRGN ESBL/MRGN
- Lassa virus Leclercia adecarboxylata, Legionella pneumophila, Leishmania spp., Leptospira interrogans, Leuconostoc pseudomesenteroides, Listeria monocytogenes, Marburg virus, Measles virus, Micrococcus luteus, Microsporum spp., Molluscipoxvirus, Morganella spp., Mumps virus, Mycobacterium chimaera Myco, Mycobacterium leprae Myco, Mycobacterium tuberculosis (incl.
- MDR Tuberculocidal, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria meningitides, Neisseria gonorrhoeae, Norovirus, Opisthorchis viverrini, Orientia tsutsugamushi, Pantoea agglomerans, Paracoccus yeei, Parainfluenza virus, Parvovirus, Pediculus humanus capitis, Pediculus humanus corporis, Plasmodium spp., Pneumocystis jiroveci, Poliovirus, Polyomavirus, Prevotella spp., Propionibacterium species, Proteus mirabilis (incl.
- Proteus vulgaris Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas spp., Rabies virus, Ralstonia spp., Respiratory syncytial virus - RSV, Rhinovirus, Rickettsia prowazekii, Rickettsia typhi, Roseomonas gilardii, Rotavirus, Rubella virus, Schistosoma mansoni, Salmonella enteritidis, Salmonella paratyphi, Salmonella spp., Salmonella typhimurium, Sarcoptes scabiei (Itch mite), Sapovirus, Serratia marcescens (incl.
- ESBL/MRGN Shigella sonnei, Sphingomonas species, Spirochaetaceae (inc. Brachyspira hyodysenteriae), Staphylococcus aureus (incl. MRSA, VRSA), Staphylococcus capitis, Staphylococcus epidermidis (incl.
- MRSE Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus pasteuri, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus pyogenes (incl.
- PRSP Streptococcus spp.
- Strongyloides stercoralis Taenia solium, TBE virus, Toxoplasma gondii, Treponema pallidum, Trichinella spiralis, Trichomonas vaginalis, Trichophyton spp., Trichosporon spp., Trichuris trichiura, Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Vaccinia virus, Varicella zoster virus, Variola virus, Vibrio cholerae, West Nile virus (WNV), Yellow fever virus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Zika virus and any combination thereof.
- WNV West Nile virus
- Yellow fever virus Yersinia enterocolitica
- Yersinia pestis Yersinia pseudo
- pathogens are pathogenic bacteria, selected from a group consisting of bacteria families Actinomyces, Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Clostridium, Corynebacterium, Enterococcus, Escherichia, Escherichia coli, Francisell, Haemophilus, Helicobacter, Helicobacter pylori, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Prevotellaceae, Pseudomonas, Rickettsia, Salmonella, Shigella, Spirochaetaceae, Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, Yersinia, and any combination thereof. It is another object of the present invention to
- compositions as defined in any of the above, wherein the composition is in the form selected from the group consisting of a tablet, a capsule, a pill, lyophilized, powder, emulsion, powder, cream, ointment, paste, lotion, gel, liquid, a solution, a patch, suspension, granulated powder, liquid, syrup, cream, foam, capsule, suppository, enema, infusion, enteric-coated pill, enteric-coated capsule, mouth wash, toothpaste, and any combination thereof.
- the composition is in the form selected from the group consisting of a tablet, a capsule, a pill, lyophilized, powder, emulsion, powder, cream, ointment, paste, lotion, gel, liquid, a solution, a patch, suspension, granulated powder, liquid, syrup, cream, foam, capsule, suppository, enema, infusion, enteric-coated pill, enteric-coated capsule, mouth wash, toothpaste, and any combination thereof.
- compositions as defined in any of the above, wherein said composition is configured to be administrable in a manner selected from a group consisting of fast release, slow release, sustained release, controlled release and any combination thereof.
- composition is an oral isotonic composition characterized by no residual chlorine taste.
- Astrovirus Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Bacteriodes fragilis, Bartonella quintana, Blastocystis hominis, Bordetella pertussis, Borrelia burgdorferi, Borrelia duttoni, Borrelia recurrentis, Brevundimonas diminuta, Brevundimonas vesicularisBrucella spp., Burkholderia cepacia (incl.
- Corynebacterium diphtheria Corynebacterium pseudotuberculosis, Corynebacterium spp., Corynebacterium ulcerans, Coxiella burnetii, Coxsackievirus, Crimean-Congo haemorrhagic fever virus, Cryptococcus neof ormans, Cryptosporidium hominis, Cryptosporidium parvum e, Cyclospora cayetanensisCytomegalovirus
- EHEC EHEC
- EPEC ETEC
- EIEC EAEC
- ESBL/MRGN DAEC
- Filarial worms Foot-and-mouth disease virus (FMDV)
- Francisella tularensis Giardia lamblia, Haemophilus influenza, Hantavirus, Helicobacter pylori, Helminths (Worms), Hepatitis A virus
- HAV Hepatitis B virus - HBV
- Hepatitis C virus - HCV Hepatitis D virus
- Hepatitis E virus Herpes simplex virus - HSV, Histoplasma capsulatum
- Human enterovirus 71 Human herpesvirus 6 (HHV-6), Human herpesvirus 7 (HHV-7), Human herpesvirus 8 (HHV-8), Human immunodeficiency virus - HIV, Human metapneumovirus, Human papillomavirus, Hymenolepsis nana, Influenza virus, Klebsiella granulomatis, Klebsiella oxytoca (incl. ESBL/MRGN), Klebsiella pneumoniae MDR (incl.
- ESBL/MRGN ESBL/MRGN
- Lassa virus Leclercia adecarboxylata, Legionella pneumophila, Leishmania spp., Leptospira interrogans, Leuconostoc pseudomesenteroides, Listeria monocytogenes, Marburg virus, Measles virus, Micrococcus luteus, Microsporum spp., Molluscipoxvirus, Morganella spp., Mumps virus, Mycobacterium chimaera Myco, Mycobacterium leprae Myco, Mycobacterium tuberculosis (incl.
- MDR Tuberculocidal, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria meningitides, Neisseria gonorrhoeae, Norovirus, Opisthorchis viverrini, Orientia tsutsugamushi, Pantoea agglomerans, Paracoccus yeei, Parainfluenza virus, Parvovirus, Pediculus humanus capitis, Pediculus humanus corporis, Plasmodium spp., Pneumocystis jiroveci, Poliovirus, Polyomavirus, Prevotella spp., Propionibacterium species, Proteus mirabilis (incl.
- Proteus vulgaris Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas spp., Rabies virus, Ralstonia spp., Respiratory syncytial virus - RSV, Rhinovirus, Rickettsia prowazekii, Rickettsia typhi, Roseomonas gilardii, Rotavirus, Rubella virus, Schistosoma mansoni, Salmonella enteritidis, Salmonella paratyphi, Salmonella spp., Salmonella typhimurium, Sarcoptes scabiei ( Itch mite), Sapovirus, Serratia marcescens (incl.
- ESBL/MRGN Shigella sonnei, Sphingomonas species, Spirochaetaceae (inc. Brachyspira hyodysenteriae ), Staphylococcus aureus (incl. MRSA, VRSA), Staphylococcus capitis, Staphylococcus epidermidis (incl.
- MRSE Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus pasteuri, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus pyogenes (incl.
- PRSP Streptococcus spp.
- Strongyloides stercoralis Taenia solium, TBE virus, Toxoplasma gondii, Treponema pallidum, Trichinella spiralis, Trichomonas vaginalis, Trichophyton spp., Trichosporon spp., Trichuris trichiura, Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Vaccinia virus, Varicella zoster virus, Variola virus, Vibrio cholerae, West Nile virus (WNV), Yellow fever virus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Zika virus and any combination thereof.
- WNV West Nile virus
- Yellow fever virus Yersinia enterocolitica
- Yersinia pestis Yersinia pseudo
- pathogens are pathogenic bacteria, selected from a group consisting of bacteria families Actinomyces, Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Clostridium, Corynebacterium, Enterococcus, Escherichia, Escherichia coli, Francis ell, Haemophilus, Helicobacter, Helicobacter pylori, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Prevotellaceae, Pseudomonas, Rickettsia, Salmonella, Shigella, Spirochaetaceae , Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, Yersinia and any combination thereof.
- composition is in the form selected from the group consisting of a tablet, a capsule, a pill, lyophilized, powder, emulsion, powder, cream, ointment, paste, lotion, gel, liquid, a solution, a patch, suspension, granulated powder, liquid, syrup, cream, foam, capsule, suppository, enema, infusion, enteric-coated pill, enteric-coated capsule, mouth wash, toothpaste, and any combination thereof.
- composition is configured to be administrable in a manner selected from a group consisting of fast release, slow release, sustained release, controlled release and any combination thereof.
- livestock refers to domesticated animals raised in an agricultural setting to produce labor and commodities such as meat, eggs, milk, fur, leather, and wool. Livestock includes beef and dairy cattle, pigs, sheep, goats, horses, mules, asses, buffalo, alpaca and camels; as well as the raising of birds commercially for meat or eggs, i.e., chickens, turkeys, ducks, geese, guinea fowl, and squabs.
- pathogen generally refers hereinafter to biological agent or micro organism (microbe) capable of producing disease in the host; i.e. a pathogen or infectious agent is a biological agent that causes disease or illness to its host.
- Pathogen is a micro-organism that may be inter alia bacteria, viruses, fungi, prions, parasites, or protozoan.
- Pathogens comprise the following: Acinetobacter baumannii, Acinetobacter Iwoffii, Acinetobacter spp. (incl. MDR), Actinomycetes, Adenovirus, Aeromonas spp., Alcaligenes faecalis, Alcaligenes spp./Achromobacter spp. Alcaligenes xylosoxidans (incl. ESBL/MRGN), Arbovirus Virucidal, Ascaris lumbricoides, Aspergillus spp.
- Astrovirus Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Bacteriodes fragilis, Bartonella quintana, Blastocystis hominis, Bordetella pertussis, Borrelia burgdorferi, Borrelia duttoni, Borrelia recurrentis, Brevundimonas diminuta, Brevundimonas vesicularisBrucella spp., Burkholderia cepacia (incl.
- Corynebacterium diphtheria Corynebacterium pseudotuberculosis, Corynebacterium spp.
- Corynebacterium ulcerans Coxiella burnetii, Coxsackievirus, Crimean-Congo haemorrhagic fever virus, Cryptococcus neoformans, Cryptosporidium hominis, Cryptosporidium parvum e, Cyclospora cayetanensisCytomegalovirus - CMV, Dengue virus, Dientamoeba fragilis, Ebola virus, Echinococcus spp,.
- Echovirus Entamoeba dispar, Entamoeba histolytica, Enterobacter aero genes, Enterobacter cloacae (incl. ESBL/MRGN), Enterobius vermicularis, Enterococcus faecalis (incl. VRE), Enterococcus faecium (incl. VRE), Enterococcus hirae, Epidermophyton spp. Epstein-Barr virus EBV, Escherichia coli (incl.
- EHEC EHEC
- EPEC ETEC
- EIEC EAEC
- ESBL/MRGN DAEC
- Filarial worms Foot-and-mouth disease virus
- FMDV Francisella tularensis
- Giardia lamblia Haemophilus influenza
- Hantavirus Helicobacter pylori
- Helminths Helminths (Worms)
- Hepatitis A virus - HAV Hepatitis B virus - HBV
- Hepatitis C virus - HCV Hepatitis D virus
- Hepatitis E virus Herpes simplex virus - HSV, Histoplasma capsulatum
- Human enterovirus 71 Human herpesvirus 6 (HHV-6), Human herpesvirus 7 (HHV-7), Human herpesvirus 8 (HHV-8), Human immunodeficiency virus - HIV, Human metapneumovirus, Human papillomavirus, Hymenolepsis nana, Influenza
- ESBL/MRGN Klebsiella pneumoniae MDR
- ESBL/MRGN Klebsiella pneumoniae MDR
- Lassa virus Leclercia adecarboxylata, Legionella pneumophila, Leishmania spp., Leptospira interrogans, Leuconostoc pseudomesenteroides, Listeria monocytogenes, Marburg virus, Measles virus, Micrococcus luteus, Microsporum spp., Molluscipoxvirus, Morganella spp., Mumps virus, Mycobacterium chimaera Myco, Mycobacterium leprae Myco, Mycobacterium tuberculosis (incl.
- MDR Tuberculocidal, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria meningitides, Neisseria gonorrhoeae, Norovirus, Opisthorchis viverrini, Orientia tsutsugamushi, Pantoea agglomerans, Paracoccus yeei, Parainfluenza virus, Parvovirus, Pediculus humanus capitis, Pediculus humanus corporis, Plasmodium spp., Pneumocystis jiroveci, Poliovirus, Polyomavirus, Prevotella spp., Propionibacterium species, Proteus mirabilis (incl.
- Proteus vulgaris Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas spp., Rabies virus, Ralstonia spp., Respiratory syncytial virus - RSV, Rhinovirus, Rickettsia prowazekii, Rickettsia typhi, Roseomonas gilardii, Rotavirus, Rubella virus, Schistosoma mansoni, Salmonella enteritidis, Salmonella paratyphi, Salmonella spp., Salmonella typhimurium, Sarcoptes scabiei ( Itch mite), Sapovirus, Serratia marcescens (incl.
- ESBL/MRGN Shigella sonnei, Sphingomonas species, Spirochaetaceae (inc. Brachyspira hyodysenteriae ), Staphylococcus aureus (incl. MRSA, VRSA), Staphylococcus capitis, Staphylococcus epidermidis (incl.
- MRSE Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus pasteuri, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus pyogenes (incl.
- PRSP Streptococcus spp.
- Strongyloides stercoralis Taenia solium, TBE virus, Toxoplasma gondii, Treponema pallidum, Trichinella spiralis, Trichomonas vaginalis, Trichophyton spp., Trichosporon spp., Trichuris trichiura, Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Vaccinia virus, Varicella zoster virus, Variola virus, Vibrio cholerae, West Nile virus (WNV), Yellow fever virus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Zika virus.
- WNV West Nile virus
- Yellow fever virus Yersinia enterocolitica
- Yersinia pestis Yersinia pseudotuberculo
- pathogenic bacteria generally refers hereinafter to bacteria that can cause disease.
- a pathogenic bacterium comprises the following bacteria families: Actinomyces, Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Clostridium, Corynebacterium, Enterococcus, Escherichia, Escherichia coli, Francis ell, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Prevotellaceae, Pseudomonas, Rickettsia, Salmonella, Shigella, Spirochaetaceae, Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, Yersinia.
- gut pathogens refers hereinafter to gastrointestinal pathogenic bacteria, viruses, fungi, prions, parasites, or protozoan, comprising inter alia bacteria of the following types: Escherichia Coli, Salmonella, Campylobacter, Virio cholera, Shigella, Clostridium pertingens, Bacillus cereus, and Yersnia entercolitica while pathogen viruses comprise inter alia rotavirus and small round viruses.
- steviol refers hereinafter to steviol glycoside, Rebaudioside A extract.
- the current invention discloses compositions and methods for controlling pathogens; eradicating, eliminating or reducing counts of pathogens in mammalian subjects.
- the current invention refers to the enterotrophic effect of an isotonic composition, Px, when administered to piglets during the first week of life and Px-gruel when administered in the immediate pre-and post- weaning period, resulting in significant reductions in intestinal E. coli load in the Px- administered piglets.
- compositions, products and formulations comprise or based on commercially available Px (trade mark) by Tonisity International Ltd, namely, a composition, e.g., defined below:
- Table 1 Ingredients of Px formulation.
- the composition consists of at least two members of a group consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate and glycine, this composition characterized by that that the composition consists of at least three members of a group consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate and glycine. Additionally or alternatively, this composition is characterized by that said composition consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate and glycine.
- a total of 56 piglets were randomly selected from each litter for euthanasia at 9 and 17 days of age and a further 20 piglets were randomly selected from each treatment group at 30 days of age.
- Samples of small intestine and ingesta from each piglet were evaluated for differences in intestinal histomorphometry, thickness of intestinal mucus layer, semi-quantitative aerobic bacterial culture, and rotaviruses PCR at the University of Minnesota Veterinary Diagnostic Laboratory.
- Samples taken from the ileal mucosa of each piglet were also submitted for semiquantitative aerobic bacterial culture (E. coli). Table 3. Test Products
- Test product was given to the litters as follows:
- pans of Px was placed in each farrowing pen and filled once daily with 500 mL of solution per day.
- Px litters were given 2 lb/litter ( ⁇ 65 g/pig) of Px-gruel (made with a 3% solution) in an open pan, in the farrowing pen.
- Group A control pigs had 14/26 (54%) subjects positive for E. coli, with 4 pigs having positive results for beta-hemolytic E. coli.
- Group B pigs had 7/30 (23%) subjects positive for E. coli, with 1 pig having positive results for beta-hemolytic E. coli.
- Overall (preweaning and postweaning combined) pigs from Group B tended to have fewer pigs positive for E.
- ETEC Enterotoxigenic E. coli
- Example 2 fecal samples were collected from each pig for pathogen detection and analysis.
- the analysis included 16S rRNA gene sequencing.
- 16S rRNA gene sequencing was performed using the MiSeq (Illumina) platform after PCR amplification of the 16S v4 region. Data was normalized to the lowest number of reads per pig (3157), as the rarefaction curves revealed a plateau after this point.
- Prevotella have been previously associated with intestinal disturbances due to weaning stress in pigs and are known intestinal mucus degraders, See Gresse R, Chaucheyras- Durand F, Fleury MA et al. Gut microbiota dysbiosis in postweaning piglets: understanding the keys to health. Trends Microbiol Elsevier Current Trends, 2017;25:851-873, and Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature Nature Publishing Group, 2011;473: 174-180.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present disclosure concerns an antibiotic-free composition for control of pathogens in a mammalian subject, characterized by at least three members of a group consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate, glycine, mixtures and derivatives thereof. The present disclosure concerns more particularly an antibiotic-free oral-administered isotonic composition for control of gut pathogens in mammals.
Description
COMPOSITIONS AND METHODS FOR CONTROLLING MAMMALIAN PATHOGENS
Field of the invention
The present disclosure relates to compositions and methods for controlling pathogens in mammalian subjects. More particularly, the current invention pertains to a composition and method for reduction of pathogenic bacteria by oral administration of a non- antibiotic isotonic drink.
Background of the invention
Early-life and weaning are associated with major shifts in the microbial community of the gut in both humans and other mammals. Of particular interest is the study of the gut microbiome, its evolution beginning in utero and across the lifespan, its effect on promotion of health, and its role in the development of disease; see Gritz, E. C., & Bhandari, V. (2015). The human neonatal gut microbiome: a brief review. Frontiers in pediatrics, 3, 17.
A large number of microbes are known to colonize the infant’s gut in the first days of life. The initial microbiota establishment represents a crucial stage for gut maturation and metabolic and immunologic programming and has important consequences for short- and long-term health, see Jost, T., Lacroix, C., Braegger, C., & Chassard, C. (2015). Impact of human milk bacteria and oligosaccharides on neonatal gut microbiota establishment and gut health. Nutrition reviews, 73(7), 426-437.
Pigs coexist with a diverse and dense commensal microbiota in their gastrointestinal tract. Most of these microbes are beneficial, providing necessary nutrients or protection against harmful pathogens for the host. The microbial colonization of the porcine intestine begins at birth and follows a rapid succession during the neonatal and weaning period. The intestinal immune system of the newborn piglet is poorly developed at birth and undergoes a rapid period of expansion and specialization that is not achieved before early (commercial-) weaning.
Early weaning of piglets is often accompanied by a severe growth check and diarrhea. This process is multi-factorial and it is clear that post- weaning anorexia and undernutrition are major
etiological factors. Gastrointestinal disturbances include alterations in small intestine architecture and enzyme activities. See Lalles, Jean-Paul, et al. "Nutritional management of gut health in pigs around weaning." Proceedings of the Nutrition Society 66.2 (2007): 260-268. Furthermore, the pig shares many common features of gastrointestinal physiology, microbiology, genetics and diet with humans. Pigs are particularly useful when assessing host microbe interactions because the gut microbiota is substantially more stable over time in both pigs and humans compared with rodent models.
Use of antibiotics for reducing or eradicating gut bacterial pathogens in human or in livestock such as pigs, exerts unwanted side effects, as well as antibiotic resistance on both the treated mammal, and the human consumers.
The animal agriculture sector is a major user of antibiotic drugs for disease treatment, disease control, disease prevention, and“production purposes” (such as growth promotion).
Routine use of antibiotics— in humans or animals— can encourage antimicrobial resistance, which can lead to significant human and animal health risks. Furthermore, in 2013, the U.S. Food and Drug Administration (FDA) issued final guidance on voluntarily phasing out the use of medically important antibiotics (those important for therapeutic use in humans) for livestock production purposes; see Sneeringer, S., MacDonald, J. M., Key, N., McBride, W. D., & Mathews, K. (2017). Economics of antibiotic use in US livestock production.
There is therefore an unmet need to overcome and control microbial diseases, caused by pathogens, without the use of antibiotics.
BRIEF DESCRIPTION OF THE FIGURES
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention.
Fig.l depicting a graphical presentation of a preferred embodiment of the current invention; and
Fig.2 depicting yet another graphical presentation of a preferred embodiment of the current invention.
SUMMARY OF THE INVENTION:
It is thus one object of the present invention to disclose a composition useful for an antibiotic- free composition for control of pathogens in a mammalian subject, characterized by at least three members of a group consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate, glycine, mixtures and derivatives thereof.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein said composition is an oral isotonic composition characterized by no residual chlorine taste.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein said control is reduction in counts of said pathogens in said mammalian subject compared to control mammalian subject.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein said control is elimination of said pathogens in said mammalian subject compared to control mammalian subject.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein said animal is selected from a group consisting at least one of human, cattle, pigs, sheep, goats, horses, mules, asses, buffalo, camels, chickens, turkeys, ducks, geese, guinea fowl, squabs, dogs, or cats of any age.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein said pathogens are selected from a group consisting of Acinetobacter baumannii, Acinetobacter Iwoffii, Acinetobacter spp. (incl. MDR), Actinomycetes, Adenovirus, Aeromonas spp., Alcaligenes faecalis, Alcaligenes spp./Achromobacter spp. Alcaligenes xylosoxidans (incl. ESBL/MRGN), Arbovirus Virucidal, Ascaris lumbricoides, Aspergillus spp. Astrovirus, Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Bacteriodes fragilis, Bartonella quintana, Blastocystis hominis, Bordetella pertussis, Borrelia burgdorferi, Borrelia duttoni, Borrelia recurrentis, Brevundimonas diminuta, Brevundimonas vesicularisBrucella spp., Burkholderia cepacia (incl. MDR), Burkholderia mallei, Burkholderia pseudomalle, Campylobacter jejuni / coliCandida albicans, Candida krusei, Candida parapsilosis, Chikungunya virus (CHIKV), Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Citrobacter spp., Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani,
Coronavirus (incl. SARS- and MERS-CoV), Corynebacterium diphtheria, Corynebacterium pseudotuberculosis, Corynebacterium spp., Corynebacterium ulcerans, Coxiella burnetii, Coxsackievirus, Crimean-Congo haemorrhagic fever virus, Cryptococcus neof ormans, Cryptosporidium hominis, Cryptosporidium parvum e, Cyclospora cayetanensisCytomegalovirus
- CMV, Dengue virus, Dientamoeba fragilis, Ebola virus, Echinococcus spp,. Echovirus, Entamoeba dispar, Entamoeba histolytica, Enterobacter aero genes, Enterobacter cloacae ( incl. ESBL/MRGN), Enterobius vermicularis, Enterococcus faecalis (incl. VRE), Enterococcus faecium (incl. VRE), Enterococcus hirae, Epidermophyton spp. Epstein-Barr virus EBV, Escherichia coli (incl. EHEC, EPEC, ETEC, EIEC, EAEC, ESBL/MRGN, DAEC), Filarial worms, Foot-and-mouth disease virus (FMDV), Francisella tularensis, Giardia lamblia, Haemophilus influenza, Hantavirus, Helicobacter pylori, Helminths (Worms), Hepatitis A virus
- HAV, Hepatitis B virus - HBV, Hepatitis C virus - HCV, Hepatitis D virus, Hepatitis E virus, Herpes simplex virus - HSV, Histoplasma capsulatum, Human enterovirus 71, Human herpesvirus 6 (HHV-6), Human herpesvirus 7 (HHV-7), Human herpesvirus 8 (HHV-8), Human immunodeficiency virus - HIV, Human metapneumovirus, Human papillomavirus, Hymenolepsis nana, Influenza virus, Klebsiella granulomatis, Klebsiella oxytoca (incl. ESBL/MRGN), Klebsiella pneumoniae MDR (incl. ESBL/MRGN), Lassa virus, Leclercia adecarboxylata, Legionella pneumophila, Leishmania spp., Leptospira interrogans, Leuconostoc pseudomesenteroides, Listeria monocytogenes, Marburg virus, Measles virus, Micrococcus luteus, Microsporum spp., Molluscipoxvirus, Morganella spp., Mumps virus, Mycobacterium chimaera Myco, Mycobacterium leprae Myco, Mycobacterium tuberculosis (incl. MDR) Tuberculocidal, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria meningitides, Neisseria gonorrhoeae, Norovirus, Opisthorchis viverrini, Orientia tsutsugamushi, Pantoea agglomerans, Paracoccus yeei, Parainfluenza virus, Parvovirus, Pediculus humanus capitis, Pediculus humanus corporis, Plasmodium spp., Pneumocystis jiroveci, Poliovirus, Polyomavirus, Prevotella spp., Propionibacterium species, Proteus mirabilis (incl. ESBL/MRGN), Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas spp., Rabies virus, Ralstonia spp., Respiratory syncytial virus - RSV, Rhinovirus, Rickettsia prowazekii, Rickettsia typhi, Roseomonas gilardii, Rotavirus, Rubella virus, Schistosoma mansoni, Salmonella enteritidis, Salmonella paratyphi, Salmonella spp., Salmonella typhimurium, Sarcoptes scabiei (Itch mite), Sapovirus, Serratia marcescens (incl. ESBL/MRGN),
Shigella sonnei, Sphingomonas species, Spirochaetaceae (inc. Brachyspira hyodysenteriae), Staphylococcus aureus (incl. MRSA, VRSA), Staphylococcus capitis, Staphylococcus epidermidis (incl. MRSE), Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus pasteuri, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus pyogenes (incl. PRSP), Streptococcus spp., Strongyloides stercoralis, Taenia solium, TBE virus, Toxoplasma gondii, Treponema pallidum, Trichinella spiralis, Trichomonas vaginalis, Trichophyton spp., Trichosporon spp., Trichuris trichiura, Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Vaccinia virus, Varicella zoster virus, Variola virus, Vibrio cholerae, West Nile virus (WNV), Yellow fever virus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Zika virus and any combination thereof.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein said pathogens are gut pathogens.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein said gut pathogen is Escherichia coli.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein said gut pathogen is Brachyspira hyodysenteriae.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein said gut pathogen is Helicobacter pylori.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein said gut pathogen is a member of the Prevotellaceae family.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein said pathogens are pathogenic bacteria, selected from a group consisting of bacteria families Actinomyces, Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Clostridium, Corynebacterium, Enterococcus, Escherichia, Escherichia coli, Francisell, Haemophilus, Helicobacter, Helicobacter pylori, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Prevotellaceae, Pseudomonas, Rickettsia, Salmonella, Shigella, Spirochaetaceae, Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, Yersinia, and any combination thereof.
It is another object of the present invention to disclose the composition as defined in any of the above wherein said pathogens are gut pathogens selected from the group consisting of bacteria, viruses, fungi, prions, parasites, or protozoan and any combination thereof.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein the composition is in the form selected from the group consisting of a tablet, a capsule, a pill, lyophilized, powder, emulsion, powder, cream, ointment, paste, lotion, gel, liquid, a solution, a patch, suspension, granulated powder, liquid, syrup, cream, foam, capsule, suppository, enema, infusion, enteric-coated pill, enteric-coated capsule, mouth wash, toothpaste, and any combination thereof.
It is another object of the present invention to disclose the composition as defined in any of the above, wherein said composition is configured to be administrable in a manner selected from a group consisting of fast release, slow release, sustained release, controlled release and any combination thereof.
It is thus one object of the present invention to disclose a method of controlling pathogens in a mammalian subject, comprising steps of providing an antibiotic-free composition characterized by at least three members of a group consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate, glycine, mixtures and derivatives thereof.
It is another object of the present invention to disclose the method as defined in any of the above, wherein said composition is an oral isotonic composition characterized by no residual chlorine taste.
It is another object of the present invention to disclose the method as defined in any of the above, wherein said step of controlling is reducing the counts of said pathogens in said mammalian subject, compared to control mammalian subject.
It is another object of the present invention to disclose the method as defined in any of the above, wherein said step of controlling is eliminating said pathogens in said mammalian subject compared to control mammalian subject.
It is another object of the present invention to disclose the method as defined in any of the above, wherein said animal is selected from a group consisting at least one of humans, cattle, pigs, sheep,
goats, horses, mules, asses, buffalo, camels, chickens, turkeys, ducks, geese, guinea fowl, squabs, dogs, or cats of any age.
It is another object of the present invention to disclose the method as defined in any of the above, wherein said pathogens are selected from a group consisting Acinetobacter baumannii, Acinetobacter Iwoffii, Acinetobacter spp. (incl. MDR), Actinomycetes, Adenovirus, Aeromonas spp., Alcaligenes faecalis, Alcaligenes spp./Achromobacter spp. Alcaligenes xylosoxidans (incl. ESBL/MRGN), Arbovirus Virucidal, Ascaris lumbricoides, Aspergillus spp. Astrovirus, Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Bacteriodes fragilis, Bartonella quintana, Blastocystis hominis, Bordetella pertussis, Borrelia burgdorferi, Borrelia duttoni, Borrelia recurrentis, Brevundimonas diminuta, Brevundimonas vesicularisBrucella spp., Burkholderia cepacia (incl. MDR), Burkholderia mallei, Burkholderia pseudomalle, Campylobacter jejuni / coliCandida albicans, Candida krusei, Candida parapsilosis, Chikungunya virus (CHIKV), Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Citrobacter spp., Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Coronavirus (incl. SARS- and MERS-CoV), Corynebacterium diphtheria, Corynebacterium pseudotuberculosis, Corynebacterium spp., Corynebacterium ulcerans, Coxiella burnetii, Coxsackievirus, Crimean-Congo haemorrhagic fever virus, Cryptococcus neof ormans, Cryptosporidium hominis, Cryptosporidium parvum e, Cyclospora cayetanensisCytomegalovirus
- CMV, Dengue virus, Dientamoeba fragilis, Ebola virus, Echinococcus spp,. Echovirus, Entamoeba dispar, Entamoeba histolytica, Enterobacter aero genes, Enterobacter cloacae ( incl. ESBL/MRGN), Enterobius vermicularis, Enterococcus faecalis (incl. VRE), Enterococcus faecium (incl. VRE), Enterococcus hirae, Epidermophyton spp. Epstein-Barr virus EBV, Escherichia coli (incl. EHEC, EPEC, ETEC, EIEC, EAEC, ESBL/MRGN, DAEC), Filarial worms, Foot-and-mouth disease virus (FMDV), Francisella tularensis, Giardia lamblia, Haemophilus influenza, Hantavirus, Helicobacter pylori, Helminths (Worms), Hepatitis A virus
- HAV, Hepatitis B virus - HBV, Hepatitis C virus - HCV, Hepatitis D virus, Hepatitis E virus, Herpes simplex virus - HSV, Histoplasma capsulatum, Human enterovirus 71, Human herpesvirus 6 (HHV-6), Human herpesvirus 7 (HHV-7), Human herpesvirus 8 (HHV-8), Human immunodeficiency virus - HIV, Human metapneumovirus, Human papillomavirus, Hymenolepsis nana, Influenza virus, Klebsiella granulomatis, Klebsiella oxytoca (incl. ESBL/MRGN), Klebsiella pneumoniae MDR (incl. ESBL/MRGN), Lassa virus, Leclercia adecarboxylata,
Legionella pneumophila, Leishmania spp., Leptospira interrogans, Leuconostoc pseudomesenteroides, Listeria monocytogenes, Marburg virus, Measles virus, Micrococcus luteus, Microsporum spp., Molluscipoxvirus, Morganella spp., Mumps virus, Mycobacterium chimaera Myco, Mycobacterium leprae Myco, Mycobacterium tuberculosis (incl. MDR) Tuberculocidal, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria meningitides, Neisseria gonorrhoeae, Norovirus, Opisthorchis viverrini, Orientia tsutsugamushi, Pantoea agglomerans, Paracoccus yeei, Parainfluenza virus, Parvovirus, Pediculus humanus capitis, Pediculus humanus corporis, Plasmodium spp., Pneumocystis jiroveci, Poliovirus, Polyomavirus, Prevotella spp., Propionibacterium species, Proteus mirabilis (incl. ESBL/MRGN), Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas spp., Rabies virus, Ralstonia spp., Respiratory syncytial virus - RSV, Rhinovirus, Rickettsia prowazekii, Rickettsia typhi, Roseomonas gilardii, Rotavirus, Rubella virus, Schistosoma mansoni, Salmonella enteritidis, Salmonella paratyphi, Salmonella spp., Salmonella typhimurium, Sarcoptes scabiei ( Itch mite), Sapovirus, Serratia marcescens (incl. ESBL/MRGN), Shigella sonnei, Sphingomonas species, Spirochaetaceae (inc. Brachyspira hyodysenteriae ), Staphylococcus aureus (incl. MRSA, VRSA), Staphylococcus capitis, Staphylococcus epidermidis (incl. MRSE), Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus pasteuri, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus pyogenes (incl. PRSP), Streptococcus spp., Strongyloides stercoralis, Taenia solium, TBE virus, Toxoplasma gondii, Treponema pallidum, Trichinella spiralis, Trichomonas vaginalis, Trichophyton spp., Trichosporon spp., Trichuris trichiura, Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Vaccinia virus, Varicella zoster virus, Variola virus, Vibrio cholerae, West Nile virus (WNV), Yellow fever virus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Zika virus and any combination thereof.
It is another object of the present invention to disclose the method as defined in any of the above, wherein said pathogens are gut pathogens.
It is another object of the present invention to disclose the method as defined in any of the above, wherein said gut pathogen is Escherichia coli.
It is another object of the present invention to disclose the method as defined in any of the above, wherein said gut pathogen is Brachyspira hyodysenteriae.
It is another object of the present invention to disclose the method as defined in any of the above, wherein said gut pathogen is Helicobacter pylori.
It is another object of the present invention to disclose the method as defined in any of the above, wherein said gut pathogen is a member of the Prevotellaceae family.
It is another object of the present invention to disclose the method as defined in any of the above, wherein said pathogens are pathogenic bacteria, selected from a group consisting of bacteria families Actinomyces, Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Clostridium, Corynebacterium, Enterococcus, Escherichia, Escherichia coli, Francis ell, Haemophilus, Helicobacter, Helicobacter pylori, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Prevotellaceae, Pseudomonas, Rickettsia, Salmonella, Shigella, Spirochaetaceae , Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, Yersinia and any combination thereof.
It is another object of the present invention to disclose the method as defined in any of the above, wherein said pathogens are gut pathogens selected from the group consisting of bacteria, viruses, fungi, prions, parasites, or protozoan and any combination thereof.
It is another object of the present invention to disclose the method as defined in any of the above, wherein the composition is in the form selected from the group consisting of a tablet, a capsule, a pill, lyophilized, powder, emulsion, powder, cream, ointment, paste, lotion, gel, liquid, a solution, a patch, suspension, granulated powder, liquid, syrup, cream, foam, capsule, suppository, enema, infusion, enteric-coated pill, enteric-coated capsule, mouth wash, toothpaste, and any combination thereof.
It is another object of the present invention to disclose the method as defined in any of the above, wherein the composition is configured to be administrable in a manner selected from a group consisting of fast release, slow release, sustained release, controlled release and any combination thereof.
It is one object of the present invention to disclose a medical device useful for control of pathogens in a mammalian subject; comprising a delivery mechanism, a container in a fluid connection with
said delivery mechanism, wherein said container accommodates an antibiotic-free composition, characterized by at least three members of a group consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate, glycine, mixtures and derivatives thereof.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following description is provided, alongside all chapters of the present invention, so as to enable any person skilled in the art to make use of the invention and sets forth the best modes contemplated by the inventor of carrying out this invention. Various modifications, however, are adapted to remain apparent to those skilled in the art, since the generic principles of the present invention have been defined specifically to provide compositions and methods for controlling pathogens in mammalian subjects.
The term“livestock” as used herein refers to domesticated animals raised in an agricultural setting to produce labor and commodities such as meat, eggs, milk, fur, leather, and wool. Livestock includes beef and dairy cattle, pigs, sheep, goats, horses, mules, asses, buffalo, alpaca and camels; as well as the raising of birds commercially for meat or eggs, i.e., chickens, turkeys, ducks, geese, guinea fowl, and squabs.
As used herein after, the term pathogen generally refers hereinafter to biological agent or micro organism (microbe) capable of producing disease in the host; i.e. a pathogen or infectious agent is a biological agent that causes disease or illness to its host. Pathogen is a micro-organism that may be inter alia bacteria, viruses, fungi, prions, parasites, or protozoan.
Pathogens comprise the following: Acinetobacter baumannii, Acinetobacter Iwoffii, Acinetobacter spp. (incl. MDR), Actinomycetes, Adenovirus, Aeromonas spp., Alcaligenes faecalis, Alcaligenes spp./Achromobacter spp. Alcaligenes xylosoxidans (incl. ESBL/MRGN), Arbovirus Virucidal, Ascaris lumbricoides, Aspergillus spp. Astrovirus, Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Bacteriodes fragilis, Bartonella quintana, Blastocystis hominis, Bordetella pertussis, Borrelia burgdorferi, Borrelia duttoni, Borrelia recurrentis, Brevundimonas diminuta, Brevundimonas vesicularisBrucella spp., Burkholderia cepacia (incl. MDR), Burkholderia mallei, Burkholderia pseudomalle, Campylobacter jejuni / coliCandida albicans, Candida krusei,
Candida parapsilosis, Chikungunya virus (CHIKV), Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Citrobacter spp., Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Coronavirus (incl. SARS- and MERS-CoV), Corynebacterium diphtheria, Corynebacterium pseudotuberculosis, Corynebacterium spp., Corynebacterium ulcerans, Coxiella burnetii, Coxsackievirus, Crimean-Congo haemorrhagic fever virus, Cryptococcus neoformans, Cryptosporidium hominis, Cryptosporidium parvum e, Cyclospora cayetanensisCytomegalovirus - CMV, Dengue virus, Dientamoeba fragilis, Ebola virus, Echinococcus spp,. Echovirus, Entamoeba dispar, Entamoeba histolytica, Enterobacter aero genes, Enterobacter cloacae (incl. ESBL/MRGN), Enterobius vermicularis, Enterococcus faecalis (incl. VRE), Enterococcus faecium (incl. VRE), Enterococcus hirae, Epidermophyton spp. Epstein-Barr virus EBV, Escherichia coli (incl. EHEC, EPEC, ETEC, EIEC, EAEC, ESBL/MRGN, DAEC), Filarial worms, Foot-and-mouth disease virus (FMDV), Francisella tularensis, Giardia lamblia, Haemophilus influenza, Hantavirus, Helicobacter pylori, Helminths (Worms), Hepatitis A virus - HAV, Hepatitis B virus - HBV, Hepatitis C virus - HCV, Hepatitis D virus, Hepatitis E virus, Herpes simplex virus - HSV, Histoplasma capsulatum, Human enterovirus 71, Human herpesvirus 6 (HHV-6), Human herpesvirus 7 (HHV-7), Human herpesvirus 8 (HHV-8), Human immunodeficiency virus - HIV, Human metapneumovirus, Human papillomavirus, Hymenolepsis nana, Influenza virus, Klebsiella granulomatis, Klebsiella oxytoca (incl. ESBL/MRGN), Klebsiella pneumoniae MDR (incl. ESBL/MRGN), Lassa virus, Leclercia adecarboxylata, Legionella pneumophila, Leishmania spp., Leptospira interrogans, Leuconostoc pseudomesenteroides, Listeria monocytogenes, Marburg virus, Measles virus, Micrococcus luteus, Microsporum spp., Molluscipoxvirus, Morganella spp., Mumps virus, Mycobacterium chimaera Myco, Mycobacterium leprae Myco, Mycobacterium tuberculosis (incl. MDR) Tuberculocidal, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria meningitides, Neisseria gonorrhoeae, Norovirus, Opisthorchis viverrini, Orientia tsutsugamushi, Pantoea agglomerans, Paracoccus yeei, Parainfluenza virus, Parvovirus, Pediculus humanus capitis, Pediculus humanus corporis, Plasmodium spp., Pneumocystis jiroveci, Poliovirus, Polyomavirus, Prevotella spp., Propionibacterium species, Proteus mirabilis (incl. ESBL/MRGN), Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas spp., Rabies virus, Ralstonia spp., Respiratory syncytial virus - RSV, Rhinovirus, Rickettsia prowazekii, Rickettsia typhi, Roseomonas gilardii, Rotavirus, Rubella virus, Schistosoma mansoni, Salmonella
enteritidis, Salmonella paratyphi, Salmonella spp., Salmonella typhimurium, Sarcoptes scabiei ( Itch mite), Sapovirus, Serratia marcescens (incl. ESBL/MRGN), Shigella sonnei, Sphingomonas species, Spirochaetaceae (inc. Brachyspira hyodysenteriae ), Staphylococcus aureus (incl. MRSA, VRSA), Staphylococcus capitis, Staphylococcus epidermidis (incl. MRSE), Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus pasteuri, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus pyogenes (incl. PRSP), Streptococcus spp., Strongyloides stercoralis, Taenia solium, TBE virus, Toxoplasma gondii, Treponema pallidum, Trichinella spiralis, Trichomonas vaginalis, Trichophyton spp., Trichosporon spp., Trichuris trichiura, Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Vaccinia virus, Varicella zoster virus, Variola virus, Vibrio cholerae, West Nile virus (WNV), Yellow fever virus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Zika virus.
As used herein after, the term pathogenic bacteria generally refers hereinafter to bacteria that can cause disease. A pathogenic bacterium comprises the following bacteria families: Actinomyces, Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Clostridium, Corynebacterium, Enterococcus, Escherichia, Escherichia coli, Francis ell, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Prevotellaceae, Pseudomonas, Rickettsia, Salmonella, Shigella, Spirochaetaceae, Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, Yersinia.
As used herein after, the term gut pathogens refers hereinafter to gastrointestinal pathogenic bacteria, viruses, fungi, prions, parasites, or protozoan, comprising inter alia bacteria of the following types: Escherichia Coli, Salmonella, Campylobacter, Virio cholera, Shigella, Clostridium pertingens, Bacillus cereus, and Yersnia entercolitica while pathogen viruses comprise inter alia rotavirus and small round viruses.
The term“steviol” refers hereinafter to steviol glycoside, Rebaudioside A extract.
The current invention discloses compositions and methods for controlling pathogens; eradicating, eliminating or reducing counts of pathogens in mammalian subjects. Specifically, the current invention refers to the enterotrophic effect of an isotonic composition, Px, when administered to piglets during the first week of life and Px-gruel when administered in the immediate pre-and post-
weaning period, resulting in significant reductions in intestinal E. coli load in the Px- administered piglets.
It is in the scope of the invention wherein aforesaid non-genetically-modified compositions, products and formulations comprise or based on commercially available Px (trade mark) by Tonisity International Ltd, namely, a composition, e.g., defined below:
Table 1: Ingredients of Px formulation.
Ingredients (%)
glucose anhydrous 1.5540
monosodium glutamate 0.3900
sodium chloride, vacuum dried 0.2201
citric acid anhydrous 0.1860
potassium chloride 0.1500
glycine 0.1500
hydrolyzed whey protein isolate 0.1500
monosodium dihydrogen phosphate 0.1000
xanthan gum 0.0500
l-glutamic acid 0.0400
stevia (min. 85 % steviol glycoside extract) 0.0100 demineralized water 97.000
The sum of all solutes in the Px solution is 3%. The composition consists of at least two members of a group consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate and glycine, this composition characterized by that that the composition consists of at least three members of a group consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate and glycine. Additionally or alternatively, this composition is characterized by that said composition consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate and glycine.
EXAMPLE 1
Two basic morphometric histopathology studies were done to investigate the effects of Tonisity Px when administered to piglets from days 2 to 8 of age and when given for 3 days before and after weaning. These studies showed a significant increase in villi height in the Px group. The effect related to whether or not Px had been given from days 2 to 8.
Introduction The rapid development of the intestinal environment in the neonatal pig sets the stage for production performance as well as nutrient absorption in the intestine. The aim of this study was to assess the effect of an isotonic protein drink on intestinal morphology and microbial population in the first 30 days of the pig’s life.
Materials and Methods Fifteen (15) gilts (Yorkshire x Landrace x Duroc) and their litters (161 piglets) were enrolled in the study which was performed in a dedicated high-health research facility. Litters were allocated to one of two study groups, control (Group A) or supplementation with an isotonic protein solution (Group B). Group A litters received no supplementation during the suckling or pre-weaning phase, and were given creep feed from weaning up until two days after weaning in addition to having feeder access. From days 2-8 of age, group B litters were given 500 mL of a 3% isotonic protein solution once daily in an open pan. Group B litters also received the 3% solution three and two days before weaning followed by a gruel mixture from one day before weaning up until two days after weaning. Weaning was at 21 days.
Table 2: Treatment Groups
A total of 56 piglets were randomly selected from each litter for euthanasia at 9 and 17 days of age and a further 20 piglets were randomly selected from each treatment group at 30 days of age. (Samples of small intestine and ingesta from each piglet were evaluated for differences in intestinal histomorphometry, thickness of intestinal mucus layer, semi-quantitative aerobic bacterial culture, and rotaviruses PCR at the University of Minnesota Veterinary Diagnostic Laboratory.) Samples taken from the ileal mucosa of each piglet were also submitted for semiquantitative aerobic bacterial culture (E. coli).
Table 3. Test Products
Feeding and Treatment Administration Plan All sows were fed while in the farrowing room according to farm management practices and were fed a standard farm lactation diet. Sows had ad lib access to fresh water through the watering system. Piglets did not have access to creep feed before weaning except as indicated in the feeding schedule. Piglets had access to an automatic drinker while in the farrowing pen.
Test product was given to the litters as follows:
a. Day 2-8, pans of Px was placed in each farrowing pen and filled once daily with 500 mL of solution per day.
b. Three (3) days before weaning, Px litters were given 500 mL of 3% Px solution in an open pan, in the farrowing pen.
c. Two (2) days before weaning, Px litters were given 500 mL of 3% Px solution in an open pan, in the farrowing pen.
d. One day before weaning, Px litters were given 2 lb/litter (~ 65 g/pig) of Px-gruel (made with a 3% solution) in an open pan, in the farrowing pen.
e. On weaning day, all pigs were weighed individually and allotted to pens based on body weight and treatment group. Once in the weaning pens, Px pigs received 15 lb* per 30 pigs of Px-gruel (made with the concentration of Px solution and the creep feed as specified in Table 3) in a separate feeder. The 15 lbs of gruel was split into 2 portions, a.m. (¼ lb per pig) and p.m. (¼ lb per pig). Dry feed and fresh water were made available. Control pigs received no gruel.
f. The Px-gruel administration was continued for the next 3 days after weaning
* 6 lb of dry feed + 1 gallon of Px solution
Table 4. Feeding Schedule for Treatment Groups
Results Days 9 and 17 microbiology and viral PCR showed that Group B pigs had significantly fewer numbers of subjects with E. coli (P = 0.01). Group A control pigs had 14/26 (54%) subjects positive for E. coli, with 4 pigs having positive results for beta-hemolytic E. coli. Group B pigs had 7/30 (23%) subjects positive for E. coli, with 1 pig having positive results for beta-hemolytic E. coli. There was an even distribution of E. coli cases between day 9 (12 cases total, 8 in Group A and 4 in Group B) and day 17 (9 cases total, 6 in Group A and 3 in Group B).
Overall (preweaning and postweaning combined) pigs from Group B tended to have fewer pigs positive for E. coli (10/40, 25%) compared to Control pigs (15/36, 42%) (P = 0.06), representing a 40% reduction from birth until day 30 of age. See Figure 1, where the percentage of positive results for E. coli cultures is graphically represented for Group A (control group) and Group B (Px-administered pigs) on days 9 and 17 of the pigs’ life, as well as the preweaning average.
Conclusion Enterotoxigenic E. coli (ETEC) is an important pathogen in neonatal and post weaning pigs as it can negatively impact production performance. The administration of an isotonic protein drink in the first week of life was associated with significant reductions in intestinal E. coli load in this study.
EXAMPLE 2
Experiment was conducted as described in example 1. In example 2, fecal samples were collected from each pig for pathogen detection and analysis. The analysis included 16S rRNA gene sequencing. 16S rRNA gene sequencing was performed using the MiSeq (Illumina) platform after PCR amplification of the 16S v4 region. Data was normalized to the lowest number of reads per pig (3157), as the rarefaction curves revealed a plateau after this point.
PCR and genetic sequencing were preformed to detect the presence of members of the Prevotellaceae family. Some Prevotella have been previously associated with intestinal disturbances due to weaning stress in pigs and are known intestinal mucus degraders, See Gresse R, Chaucheyras- Durand F, Fleury MA et al. Gut microbiota dysbiosis in postweaning piglets: understanding the keys to health. Trends Microbiol Elsevier Current Trends, 2017;25:851-873, and Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature Nature Publishing Group, 2011;473: 174-180.
The results indicate that the presence of Prevotellaceae was significantly lower in Group B (Px- administered pigs) compared to Group A (control) at days 9 and 17 (20.5% and 27.6% vs 29.0% and 37.0%, respectively; P < 0.01). These differences represent a 29% reduction at day 9 and a 25% reduction at day 17. No differences were observed at day 30 of life. See Figure 2, where the percentage of positive results for Prevotellaceae cultures is graphically represented for Group A (control group) and Group B (Px-administered pigs) on days 9, 17 and 30 of the pigs’ life.
EXAMPLE 3
Experiment was conducted as described in example 2. PCR and genetic sequencing were preformed to detect the presence of the Spirochaetaceae family which includes the known porcine pathogen Brachyspira hyodysenteriae. This bacterium induces mucohemorrhagic diarrhea in pigs, with mortality and morbidity approaching 30% and 90%, respectively, see Schweer W.P, Gabler N.K, et al. Impact of Brachyspira hyodysenteriae on intestinal amino acid digestibility and endogenous amino acid losses in pigs.Journal of Animal Science, October, 2018;97: 1-12.
The results of the experiment show that Group B (Px-administered pigs) had lower amounts of Spirochaetaceae compared to Group A (control group) at day 9 (0.04% vs 0.15%; P < 0.05).
EXAMPLE 4
Experiment was conducted as described in example 2. PCR and genetic sequencing were preformed to detect the presence of Helicobacter pylori. Previous publications have linked the presence of this bacterium to several types of cancers, including gastric cancer, low-grade mucosa- associated lymphoid tissue (MALT) lymphoma and pancreatic ductal adenocarcinoma, see Mentis A., Papavassiliou A. G., et al. Helicobacter pylori infection and gastric cancer biology: tempering a double-edged sword. Cellular and molecular life science, July 20l9;76 (13): 2477-2486 and Wei M.Y, Yu X. G., et al. The microbiota and microbiome in pancreatic cancer: more influential than expected. Molecular Cancer, 2019;18: 1-15.
The results obtained from this experiment demonstrate that the odds of detecting Helicobacter in Group A (control group) at day 9 were 4.3 times higher than in Group B (Px-administered pigs) (P=0.08).
Claims
1. An antibiotic-free composition for control of pathogens in a mammalian subject, characterized by at least three members of a group consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate, glycine, mixtures and derivatives thereof.
2. The composition of claim 1, wherein said composition is an oral isotonic composition characterized by no residual chlorine taste.
3. The composition of claim 1, wherein said control is reduction in counts of said pathogens in said mammalian subject compared to control mammalian subject.
4. The composition of claim 1, wherein said control is elimination of said pathogens in said mammalian subject compared to control mammalian subject.
5. The composition of claim 4, wherein said animal is selected from a group consisting of at least one of human, cattle, pigs, sheep, goats, horses, mules, asses, buffalo, camels, chickens, turkeys, ducks, geese, guinea fowl, squabs, dogs, or cats of any age.
6. The composition of claim 1 , wherein said pathogens are selected from a group consisting of Acinetobacter baumannii, Acinetobacter Iwoffii, Acinetobacter spp. (incl. MDR), Actinomycetes, Adenovirus, Aeromonas spp., Alcaligenes faecalis, Alcaligenes spp./Achromobacter spp. Alcaligenes xylosoxidans (incl. ESBL/MRGN), Arbovirus Virucidal, Ascaris lumbricoides, Aspergillus spp. Astrovirus, Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Bacteriodes fragilis, Bartonella quintana, Blastocystis hominis, Bordetella pertussis, Borrelia burgdorferi, Borrelia duttoni, Borrelia recurrentis, Brevundimonas diminuta, Brevundimonas vesicularisBrucella spp., Burkholderia cepacia (incl. MDR), Burkholderia mallei, Burkholderia pseudomalle, Campylobacter jejuni / coliCandida albicans, Candida krusei, Candida parapsilosis, Chikungunya virus ( CHIKV), Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Citrobacter spp., Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Coronavirus (incl. SARS- and MERS-CoV), Corynebacterium diphtheria, Corynebacterium pseudotuberculosis, Corynebacterium spp., Corynebacterium ulcerans, Coxiella burnetii, Coxsackievirus, Crimean-Congo haemorrhagic fever virus, Cryptococcus neoformans, Cryptosporidium hominis, Cryptosporidium parvum e, Cyclospora cayetanensisCytomegalovirus - CMV, Dengue virus, Dientamoeba fragilis, Ebola virus, Echinococcus spp,. Echovirus, Entamoeba dispar, Entamoeba histolytica, Enterobacter
aero genes, Enterobacter cloacae (incl. ESBL/MRGN), Enterobius vermicularis, Enterococcus faecalis (incl. VRE), Enterococcus faecium (incl. VRE), Enterococcus hirae, Epidermophyton spp. Epstein-Barr virus EBV, Escherichia coli (incl. EHEC, EPEC, ETEC, EIEC, EAEC, ESBL/MRGN, DAEC), Filarial worms, Foot-and-mouth disease virus (FMDV), Francisella tularensis, Giardia lamblia, Haemophilus influenza, Hantavirus, Helicobacter pylori, Helminths (Worms), Hepatitis A virus - HAV, Hepatitis B virus - HBV, Hepatitis C virus - HCV, Hepatitis D virus, Hepatitis E virus, Herpes simplex virus - HSV, Histoplasma capsulatum, Human enterovirus 71, Human herpesvirus 6 (HHV-6), Human herpesvirus 7 (HHV-7), Human herpesvirus 8 (HHV-8), Human immunodeficiency virus - HIV, Human metapneumovirus, Human papillomavirus, Hymenolepsis nana, Influenza virus, Klebsiella granulomatis, Klebsiella oxytoca (incl. ESBL/MRGN), Klebsiella pneumoniae MDR (incl. ESBL/MRGN), Lassa virus, Leclercia adecarboxylata, Legionella pneumophila, Leishmania spp., Leptospira interrogans, Leuconostoc pseudomesenteroides, Listeria monocytogenes, Marburg virus, Measles virus, Micrococcus luteus, Microsporum spp., Molluscipoxvirus, Morganella spp., Mumps virus, Mycobacterium chimaera Myco, Mycobacterium leprae Myco, Mycobacterium tuberculosis (incl. MDR) Tuberculocidal, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria meningitides, Neisseria gonorrhoeae, Norovirus, Opisthorchis viverrini, Orientia tsutsugamushi, Pantoea agglomerans, Paracoccus yeei, Parainfluenza virus, Parvovirus, Pediculus humanus capitis, Pediculus humanus corporis, Plasmodium spp., Pneumocystis jiroveci, Poliovirus, Polyomavirus, Prevotella spp., Propionibacterium species, Proteus mirabilis (incl. ESBL/MRGN), Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas spp., Rabies virus, Ralstonia spp., Respiratory syncytial virus - RSV, Rhinovirus, Rickettsia prowazekii, Rickettsia typhi, Roseomonas gilardii, Rotavirus, Rubella virus, Schistosoma mansoni, Salmonella enteritidis, Salmonella paratyphi, Salmonella spp., Salmonella typhimurium, Sarcoptes scabiei (Itch mite), Sapovirus, Serratia marcescens (incl. ESBL/MRGN), Shigella sonnei, Sphingomonas species, Spirochaetaceae (inc. Brachyspira hyodysenteriae ), Staphylococcus aureus (incl. MRSA, VRSA), Staphylococcus capitis, Staphylococcus epidermidis (incl. MRSE), Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus pasteuri, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus
pneumoniae, Streptococcus pyogenes (incl. PRSP), Streptococcus spp., Strongyloides stercoralis, Taenia solium, TBE virus, Toxoplasma gondii, Treponema pallidum, Trichinella spiralis, Trichomonas vaginalis, Trichophyton spp., Trichosporon spp., Trichuris trichiura, Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Vaccinia virus, Varicella zoster virus, Variola virus, Vibrio cholerae, West Nile virus (WNV), Yellow fever virus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Zika virus and any combination thereof.
7. The composition of claim 1, wherein said pathogens are gut pathogens.
8. The composition of claim7, wherein said gut pathogen is Escherichia coli.
9. The composition of claim7, wherein said gut pathogen is Brachyspira hyodysenteriae.
10. The composition of claim7, wherein said gut pathogen is Helicobacter pylori.
11. The composition of claim7, wherein said gut pathogen is a member of the Prevotellaceae family.
12. The composition of claim 1 wherein said pathogens are pathogenic bacteria, selected from a group consisting of bacteria families Actinomyces, Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Clostridium, Corynebacterium, Enterococcus, Escherichia, Escherichia coli, Francisell, Haemophilus, Helicobacter, Helicobacter pylori, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Prevotellaceae, Pseudomonas, Rickettsia, Salmonella, Shigella, Spirochaetaceae , Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio cholera, Yersinia, and any combination thereof.
13. The composition of claim 1, wherein said pathogens are gut pathogens selected from the group consisting of bacteria, viruses, fungi, prions, parasites, or protozoan and any combination thereof.
14. The composition of claim 1, wherein the composition is in the form selected from the group consisting of a tablet, a capsule, a pill, lyophilized, powder, emulsion, powder, cream, ointment, paste, lotion, gel, liquid, a solution, a patch, suspension, granulated powder, liquid, syrup, cream, foam, capsule, suppository, enema, infusion, enteric-coated pill, enteric- coated capsule, mouth wash, toothpaste and any combination thereof.
15. The composition of claim 1, wherein said composition is configured to be administrable in a manner selected from a group consisting of fast release, slow release, sustained release, controlled release and any combination thereof.
16. A method for controlling pathogens in a mammalian subject, comprising steps of providing an antibiotic-free composition characterized by at least three members of a group consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate, glycine, mixtures and derivatives thereof.
17. The method of claim 16, wherein said composition is an oral isotonic composition characterized by no residual chlorine taste.
18. The method of claim 16, wherein said step of controlling is reducing the counts of said pathogens in said mammalian subject, compared to control mammalian subject.
19. The method of claim 16, wherein said step of controlling is eliminating said pathogens in said mammalian subject compared to control mammalian subject.
20. The method of claim 16, wherein said animal is selected from a group consisting of at least one of humans, cattle, pigs, sheep, goats, horses, mules, asses, buffalo, camels, chickens, turkeys, ducks, geese, guinea fowl, squabs, dogs, or cats of any age.
21. The method of claim 16, wherein said pathogens are selected from a group consisting of Acinetobacter baumannii, Acinetobacter Iwoffii, Acinetobacter spp. (incl. MDR), Actinomycetes, Adenovirus, Aeromonas spp., Alcaligenes faecalis, Alcaligenes spp./Achromobacter spp. Alcaligenes xylosoxidans (incl. ESBL/MRGN), Arbovirus Virucidal, Ascaris lumbricoides, Aspergillus spp. Astrovirus, Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Bacteriodes fragilis, Bartonella quintana, Blastocystis hominis, Bordetella pertussis, Borrelia burgdorferi, Borrelia duttoni, Borrelia recurrentis, Brevundimonas diminuta, Brevundimonas vesicularisBrucella spp., Burkholderia cepacia (incl. MDR), Burkholderia mallei, Burkholderia pseudomalle, Campylobacter jejuni / coliCandida albicans, Candida krusei, Candida parapsilosis, Chikungunya virus ( CHIKV), Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Citrobacter spp., Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Coronavirus (incl. SARS- and MERS-CoV), Corynebacterium diphtheria, Corynebacterium pseudotuberculosis, Corynebacterium spp., Corynebacterium ulcerans, Coxiella burnetii, Coxsackievirus, Crimean-Congo haemorrhagic fever virus, Cryptococcus neoformans,
Cryptosporidium hominis, Cryptosporidium parvum e, Cyclospora cayetanensisCytomegalovirus - CMV, Dengue virus, Dientamoeba fragilis, Ebola virus, Echinococcus spp,. Echovirus, Entamoeba dispar, Entamoeba histolytica, Enterobacter aero genes, Enterobacter cloacae (incl. ESBL/MRGN), Enterobius vermicularis, Enterococcus faecalis (incl. VRE), Enterococcus faecium (incl. VRE), Enterococcus hirae, Epidermophyton spp. Epstein-Barr virus EBV, Escherichia coli (incl. EHEC, EPEC, ETEC, EIEC, EAEC, ESBL/MRGN, DAEC), Filarial worms, Foot-and-mouth disease virus (FMDV), Francisella tularensis, Giardia lamblia, Haemophilus influenza, Hantavirus, Helicobacter pylori, Helminths (Worms), Hepatitis A virus - HAV, Hepatitis B virus - HBV, Hepatitis C virus - HCV, Hepatitis D virus, Hepatitis E virus, Herpes simplex virus - HSV, Histoplasma capsulatum, Human enterovirus 71, Human herpesvirus 6 (HHV-6), Human herpesvirus 7 (HHV-7), Human herpesvirus 8 (HHV-8), Human immunodeficiency virus - HIV, Human metapneumovirus, Human papillomavirus, Hymenolepsis nana, Influenza virus, Klebsiella granulomatis, Klebsiella oxytoca (incl. ESBL/MRGN), Klebsiella pneumoniae MDR (incl. ESBL/MRGN), Lassa virus, Leclercia adecarboxylata, Legionella pneumophila, Leishmania spp., Leptospira interrogans, Leuconostoc pseudomesenteroides, Listeria monocytogenes, Marburg virus, Measles virus, Micrococcus luteus, Microsporum spp., Molluscipoxvirus, Morganella spp., Mumps virus, Mycobacterium chimaera Myco, Mycobacterium leprae Myco, Mycobacterium tuberculosis (incl. MDR) Tuberculocidal, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria meningitides, Neisseria gonorrhoeae, Norovirus, Opisthorchis viverrini, Orientia tsutsugamushi, Pantoea agglomerans, Paracoccus yeei, Parainfluenza virus, Parvovirus, Pediculus humanus capitis, Pediculus humanus corporis, Plasmodium spp., Pneumocystis jiroveci, Poliovirus, Polyomavirus, Prevotella spp., Propionibacterium species, Proteus mirabilis (incl. ESBL/MRGN), Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas spp., Rabies virus, Ralstonia spp., Respiratory syncytial virus - RSV, Rhinovirus, Rickettsia prowazekii, Rickettsia typhi, Roseomonas gilardii, Rotavirus, Rubella virus, Schistosoma mansoni, Salmonella enteritidis, Salmonella paratyphi, Salmonella spp., Salmonella typhimurium, Sarcoptes scabiei (Itch mite), Sapovirus, Serratia marcescens (incl. ESBL/MRGN), Shigella sonnei, Sphingomonas species, Spirochaetaceae (inc. Brachyspira hyodysenteriae ), Staphylococcus aureus (incl. MRSA, VRSA),
Staphylococcus capitis, Staphylococcus epidermidis (incl. MRSE), Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus pasteuri, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus pyogenes (incl. PRSP), Streptococcus spp., Strongyloides stercoralis, Taenia solium, TBE virus, Toxoplasma gondii, Treponema pallidum, Trichinella spiralis, Trichomonas vaginalis, Trichophyton spp., Trichosporon spp., Trichuris trichiura, Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Vaccinia virus, Varicella zoster virus, Variola virus, Vibrio cholerae, West Nile virus (WNV), Yellow fever virus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Zika virus and any combination thereof.
22. The method of claim 16, wherein said pathogens are gut pathogens.
23. The method of claim 22, wherein said gut pathogen is Escherichia coli.
24. The method of claim 22, wherein said gut pathogen is Brachyspira hyodysenteriae.
25. The method of claim 22, wherein said gut pathogen is Helicobacter pylori.
26. The method of claim 22, wherein said gut pathogen is a member of the Prevotellaceae family.
27. The method of claim 16, wherein said pathogens are pathogenic bacteria, selected from a group consisting of bacteria families Actinomyces, Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Clostridium, Corynebacterium, Enterococcus, Escherichia, Escherichia coli, Francis ell, Haemophilus, Helicobacter, Helicobacter pylori, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Prevotellaceae, Pseudomonas, Rickettsia, Salmonella, Shigella, Spirochaetaceae , Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, Yersinia and any combination thereof.
28. The method of claim 16, wherein said pathogens are gut pathogens selected from the group consisting of bacteria, viruses, fungi, prions, parasites, or protozoan and any combination thereof.
29. The method of claim 16, wherein the composition is in the form selected from the group consisting of a tablet, a capsule, a pill, lyophilized, powder, emulsion, powder, cream, ointment, paste, lotion, gel, liquid, a solution, a patch, suspension, granulated powder, liquid,
syrup, cream, foam, capsule, suppository, enema, infusion, enteric-coated pill, enteric- coated capsule, mouth wash, toothpaste , and any combination thereof.
30. The method of claim 16, wherein the composition is configured to be administrable in a manner selected from a group consisting of fast release, slow release, sustained release, controlled release and any combination thereof.
31. A medical device useful for control of pathogens in a mammalian subject; comprising a delivery mechanism, a container in a fluid connection with said delivery mechanism, wherein said container accommodates an antibiotic-free composition, characterized by at least three members of a group consisting of steviol glycoside, citric acid monohydrate, monosodium glutamate, glycine, mixtures and derivatives thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721641P | 2018-08-23 | 2018-08-23 | |
| US62/721,641 | 2018-08-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2020039443A1 true WO2020039443A1 (en) | 2020-02-27 |
| WO2020039443A8 WO2020039443A8 (en) | 2020-09-17 |
Family
ID=69591394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IL2019/050942 WO2020039443A1 (en) | 2018-08-23 | 2019-08-22 | Compositions and methods for controlling mammalian pathogens |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2020039443A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1629724A1 (en) * | 2004-08-27 | 2006-03-01 | PURAC Biochem BV | The use of glycine and/or a glycine derivative as antibacterial agent in foods and/or drinks |
| CN106265810A (en) * | 2016-08-29 | 2017-01-04 | 晨光生物科技集团股份有限公司 | A kind of stevia rebaudiana phenol extract and the application in preparing antibacterial goods thereof |
| US20170339997A1 (en) * | 2014-11-19 | 2017-11-30 | Kalmarna Limited | Oral rehydration composition and methods thereof |
| US20180153841A1 (en) * | 2014-11-19 | 2018-06-07 | Kalmarna Limited | Compositions and methods for induction of remission of inflammatory bowel diseases |
| US20180214404A1 (en) * | 2014-11-19 | 2018-08-02 | Kalmarna Limited | Oral nourishing composition and methods thereof |
-
2019
- 2019-08-22 WO PCT/IL2019/050942 patent/WO2020039443A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1629724A1 (en) * | 2004-08-27 | 2006-03-01 | PURAC Biochem BV | The use of glycine and/or a glycine derivative as antibacterial agent in foods and/or drinks |
| US20170339997A1 (en) * | 2014-11-19 | 2017-11-30 | Kalmarna Limited | Oral rehydration composition and methods thereof |
| US20180153841A1 (en) * | 2014-11-19 | 2018-06-07 | Kalmarna Limited | Compositions and methods for induction of remission of inflammatory bowel diseases |
| US20180214404A1 (en) * | 2014-11-19 | 2018-08-02 | Kalmarna Limited | Oral nourishing composition and methods thereof |
| CN106265810A (en) * | 2016-08-29 | 2017-01-04 | 晨光生物科技集团股份有限公司 | A kind of stevia rebaudiana phenol extract and the application in preparing antibacterial goods thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020039443A8 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li | Current status and prospects for in-feed antibiotics in the different stages of pork production—A review | |
| Chidgey et al. | Sow and piglet productivity and sow reproductive performance in farrowing pens with temporary crating or farrowing crates on a commercial New Zealand pig farm | |
| Sørum et al. | Resistance to antibiotics in the normal flora of animals | |
| US20110171348A1 (en) | Pet food | |
| Poulsen et al. | The microbial community of the gut differs between piglets fed sow milk, milk replacer or bovine colostrum | |
| JP3026141B2 (en) | Pollution-resistant animal feed, method for producing the feed, and method for raising livestock | |
| BR112017008184B1 (en) | USES OF A COMPOSITION, LINEAGE AND COMPOSITION | |
| US20090181357A1 (en) | Method of freeze-drying sterilized rumen fluid to maintain the bioactivity of the bacterial polysaccharides | |
| RU2493725C1 (en) | Ingredients composition for fodder product for farm animals and birds | |
| WO2020039443A1 (en) | Compositions and methods for controlling mammalian pathogens | |
| Edrington et al. | A commentary on Salmonella from a pre-harvest perspective | |
| Hogg et al. | Diagnosis and implications of botulism | |
| EP3288391A1 (en) | Feed supplement additive | |
| WO2017173393A1 (en) | Clay-based materials for animal feeding and care | |
| RU2326692C2 (en) | Probiotic medicinal agent for agricultural animals and birds | |
| CN113331306A (en) | Additive for improving livestock and poultry physiological function based on yucca, and preparation method and application thereof | |
| US20210299152A1 (en) | Oral compositions and methods for affecting mammalian offspring | |
| Groffen et al. | Analysis of growth rate variables and postfeeding regurgitation in hand-reared Spix's macaw (Cyanopsitta spixii) chicks | |
| RU2352344C2 (en) | Method of cows endometritis prevention | |
| Velge et al. | Two in vivo models to study Salmonella asymptomatic carrier state in chicks | |
| CN113796465B (en) | Nutritional powder for dogs as well as preparation method and application thereof | |
| RU2535111C1 (en) | Method of application of feed additive for pigs | |
| Gladkih et al. | Prevention of transport stress in the realization of the adaptive potential of pigs | |
| Kasimanickam | Bovine respiratory disease “shipping fever” in cattle | |
| Trajchev et al. | Influence of humic acids as a feed supplement on the reproductive performance of sows |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19852018 Country of ref document: EP Kind code of ref document: A1 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 19852018 Country of ref document: EP Kind code of ref document: A1 |